Management of Recurrent Bradycardia with Shortness of Breath in Post-NSTEMI Patient with 3-Vessel CAD

Immediate Assessment and Monitoring

The European Society of Cardiology recommends continuous cardiac rhythm monitoring for >24 hours in patients with high-risk features of 3-vessel CAD and recurrent symptomatic bradycardia, with immediate assessment for ongoing ischemia, hemodynamic instability, and consideration of urgent coronary angiography if not already performed 1, 2, 3
Continuous rhythm monitoring is mandatory until the clinical picture is fully clarified, as this patient meets criteria for high-risk NSTEMI with major arrhythmias 1, 2, 3
Rhythm monitoring for >24 hours is specifically recommended for NSTEMI patients at increased risk for cardiac arrhythmias, which this patient clearly demonstrates with recurrent bradycardia episodes 1, 2, 3, 4
Admit to a monitored unit immediately - the ESC guidelines explicitly state that all NSTEMI patients should be admitted to a monitored unit, and this patient has additional high-risk features 1, 2, 3
Obtain 12-lead ECG immediately with each symptomatic episode to assess for new ST-segment changes indicating ongoing ischemia 2, 3, degree and type of bradycardia (sinus vs. AV block) 1, 2, and additional ECG leads (V3R, V4R, V7-V9) if ongoing ischemia is suspected 2, 3

Serial high-sensitivity cardiac troponin measurements are essential to determine if these episodes represent recurrent ischemia 1, 3
Measure hs-cTn at 0h and 1h using the ESC 0h/1h algorithm if available, or alternatively at 0h and 2h 2, 3
Echocardiography is recommended to evaluate regional wall motion abnormalities suggesting ongoing ischemia 2, 3, 4, left ventricular ejection fraction (LVEF <40% indicates higher risk) 1, 3, 4, and hemodynamic status 2, 3
Assess for hemodynamic instability - measure blood pressure during symptomatic episodes, as bradycardia with hypotension indicates very high-risk status requiring urgent intervention 1, 2, 3

Review all medications immediately - beta-blockers, calcium channel blockers, or other rate-limiting drugs may be contributing to symptomatic bradycardia in the setting of acute ischemia 5
Consider medication-induced bradycardia - if the patient is on beta-blockers or non-dihydropyridine calcium channel blockers, these may need dose reduction or temporary discontinuation 5
Assess for high-degree AV block - the recurrent nature and association with symptoms suggests possible Mobitz II or third-degree block, which requires different management than sinus bradycardia 1, 3

This patient has multiple high-risk features mandating urgent evaluation: 3-vessel CAD with recurrent symptoms indicates very high risk and typically requires early invasive strategy within 24 hours 1, 2, 6
Recurrent ischemia despite medical therapy (if symptomatic episodes represent ongoing ischemia) is a Class I indication for urgent coronary angiography 2, 6
Major arrhythmias (symptomatic bradycardia) classify this patient as high-risk requiring extended monitoring and consideration of urgent intervention 1, 3, 4

Anti-ischemic therapy optimization: Nitroglycerin (sublingual or IV) should be administered during symptomatic episodes unless contraindicated by hypotension (SBP <90 mmHg or >30 mmHg below baseline) or bradycardia <50 bpm 5, 7
Morphine sulfate IV may be considered for uncontrolled ischemic symptoms despite nitroglycerin, though it should be used cautiously as additional therapy to manage underlying ischemia 5, 8
Beta-blocker adjustment - if the patient is on beta-blockers and experiencing symptomatic bradycardia, these should be held or reduced 5, 8

Ensure dual antiplatelet therapy is optimized: Aspirin 75-100 mg daily should be continued indefinitely 2, 8
P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) should be continued for 12 months unless excessive bleeding risk 2, 8
Parenteral anticoagulation should be continued if not already on therapeutic anticoagulation 2, 8

Urgent angiography (<2 hours) is indicated if hemodynamic instability persists 2, 7, ongoing ischemia despite intensive medical therapy 2, 7, or life-threatening arrhythmias 2
Early angiography (within 24 hours) is indicated for recurrent symptoms despite medical therapy 2, 7, 8, 3-vessel CAD with elevated troponin 1, 6, or major arrhythmias in the setting of NSTEMI 1, 3, 4

Temporary pacing may be necessary if high-degree AV block (Mobitz II or third-degree) is documented 1, or hemodynamic compromise occurs with bradycardia 1, 2

Do not discharge or downgrade monitoring based on brief symptom resolution - the recurrent nature and 3-vessel CAD mandate extended observation 1, 3, 4
Do not delay angiography in patients with recurrent symptoms and 3-vessel CAD - this represents high-risk anatomy requiring urgent evaluation 2, 6, 7
Do not continue rate-limiting medications (beta-blockers, non-dihydropyridine calcium channel blockers) at full doses if causing symptomatic bradycardia 5
Do not administer nitrates if systolic blood pressure <90 mmHg, severe bradycardia <50 bpm, or tachycardia >100 bpm without heart failure 5
Do not use immediate-release dihydropyridine calcium channel blockers without adequate beta-blockade, and avoid in the setting of bradycardia 5, 8